A New Drug Target for Type 2 Diabetes

Lukas K J Stadler; I Sadaf Farooqi

doi:10.1016/j.cell.2017.06.024

A New Drug Target for Type 2 Diabetes

Cell. 2017 Jun 29;170(1):12-14. doi: 10.1016/j.cell.2017.06.024.

Authors

Lukas K J Stadler¹, I Sadaf Farooqi²

Affiliations

¹ University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
² University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. Electronic address: isf20@cam.ac.uk.

PMID: 28666114
DOI: 10.1016/j.cell.2017.06.024

Abstract

Genetic studies can identify novel therapeutic targets for common complex diseases. In this issue of Cell, Rusu et al. demonstrate that a cluster of genetic variants associated with an increased risk of type 2 diabetes affect the function of a monocarboxylate transporter involved in nutrient flux and hepatic lipid metabolism.

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2*
Humans
Lipid Metabolism
Lipids
Liver*

Substances

Lipids

Grants and funding

MC_UU_12012/5/MRC_/Medical Research Council/United Kingdom